Loading…
Major Chinese API and generic-drug manufacturer with a long-standing Pfizer joint venture and broad export APIs business.
Major Chinese API and generic-drug manufacturer with a long-standing Pfizer joint venture and broad export APIs business.
Sells fermentation-based ingredients and finished generics, with domestic hospital sales exposed to China's volume-based procurement, where winners of government tenders sell at much lower prices, and exports to overseas generics makers. A 2012 joint venture with Pfizer produces and markets generics in China.
Moat: narrow (scale, regulatory licence). Large-scale, FDA/EU-audited API manufacturing plus a long Pfizer joint-venture relationship.
Headquarters: Taizhou, Zhejiang, China · Employees: 8,751
Size Zhejiang Hisun Pharmaceutical (600267.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.32B, the 1098th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.40 on 6 Nov 2026.
Performance Over six months the shares gained 18.4%, against -10.5% for the median peer and -16.4% for the China market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 7.0% over the last twelve months (peer median -0.2%); the operating margin is 15.3% (peer median 8.6%).
Valuation It trades at 17.0× forward earnings against a peer median of 18.6× (6th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.4 points above its cost of capital (5.5% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.15B | CN¥10.5B | CN¥10.3B | CN¥10.3B | CN¥12.0B |
| Revenue growth | — | +2% | 0% | -14% | — |
| Gross profit | CN¥5.42B | CN¥4.26B | CN¥3.81B | CN¥3.65B | CN¥4.47B |
| EBITDA | n/a | CN¥2.08B | CN¥1.84B | CN¥1.34B | CN¥2.00B |
| Net income | CN¥1.23B | CN¥541M | CN¥601M | -CN¥93.2M | CN¥489M |
| Free cash flow | CN¥1.09B | CN¥1.67B | CN¥1.96B | CN¥1.28B | CN¥1.55B |
| Capital expenditure | CN¥503M | CN¥376M | CN¥238M | CN¥240M | CN¥531M |
| Total debt | CN¥1.71B | CN¥3.22B | CN¥4.50B | CN¥6.20B | CN¥7.16B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% |
| Apeloa Pharmaceutical 000739.SZ | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% |
| Zhejiang Medicine 600216.SS | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% |
| North China Pharmaceutical 600812.SS | $1.17B | -8% | -21% | 5% | n/a | 1.4% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
| Zhejiang NHU 002001.SZ | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600267.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.1% | -0.6% | 3rd highest of 21 |
| 6-month return | +18.4% | -10.5% | 5th highest of 21 |
| Distance from 52-week high | -10.7% | -27.1% | 4th highest of 21 |
| Revenue growth (TTM) | -7.0% | -0.2% | 6th lowest of 19 |
| Operating margin | 15.3% | 8.6% | 5th highest of 18 |
| Forward P/E | 17.0× | 18.6× | 6th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -9.1% | 2.4% | least demanding of 14 |
| Growth delivered (Del g) | -1.5% | +6.4% | 3rd lowest of 14 |
| Hurdle (Req g minus delivered) | -7.6 pp | -0.3 pp | 6th least demanding of 14 |
| ROIC minus cost of capital | +9.4 pp | -2.5 pp | 2nd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% | -1.5% |
| InnoCare Pharma 688428.SS | China | $2.31B | -2% | +135% | 35% | 94.3× | -8.8% | +344.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | n/a | -2.2% | -5.8% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 26.2× | 1.6% | +0.3% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | n/a | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% | +0.8% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 12.4× | 3.7% | +15.7% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 18.6× | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 22.8× | 6.1% | +6.4% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | n/a | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | n/a | 37.9% | +0.9% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% | +19.3% |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |